BRCA1 and neoplasm: Moreover, an ongoing phase II (NCT01078662) study of olaparib monotherapy in BRCA1/2 mutation carriers of different tumour types revealed clinical benefit in prostate and pancreatic cancer as well as activity in ovarian and breast cancer.